恒瑞医药
(600276)
| 流通市值：2801.02亿 | | | 总市值：2914.40亿 |
| 流通股本：63.79亿 | | | 总股本：66.37亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 15,455,583,728.11 | 8,140,565,320.77 | 31,629,416,193.83 | 23,188,081,928.77 |
| 营业总成本 | 11,313,140,405.95 | 5,642,928,613.81 | 23,093,097,613.72 | 16,915,649,809.76 |
| 其他经营收益 | | | | |
| 营业利润 | 5,087,742,489.21 | 2,607,443,528 | 8,990,002,841.99 | 6,624,512,439.11 |
| 利润总额 | 4,952,417,467.84 | 2,556,862,055.54 | 8,707,625,538.18 | 6,412,007,794.73 |
| 净利润 | 4,465,282,419.88 | 2,280,994,705.34 | 7,717,002,245.78 | 5,760,235,152.02 |
| 每股收益 | | | | |
| 其他综合收益 | -31,800,666.03 | -13,182,740.49 | 10,995,435.22 | 20,467,114.35 |
| 综合收益总额 | 4,433,481,753.85 | 2,267,811,964.85 | 7,727,997,681 | 5,780,702,266.37 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 49,607,557,380.05 | 52,044,194,705.35 | 51,490,372,457.04 | 51,399,537,865.51 |
| 非流动资产: | | | | |
| 非流动资产合计 | 21,165,564,618.84 | 19,249,667,735.53 | 18,376,943,316.7 | 16,928,002,620.27 |
| 资产总计 | 70,773,121,998.89 | 71,293,862,440.88 | 69,867,315,773.74 | 68,327,540,485.78 |
| 流动负债: | | | | |
| 流动负债合计 | 4,247,215,561.44 | 5,636,723,710.95 | 6,369,237,286 | 7,851,588,815.91 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,536,166,020.39 | 1,510,052,451.98 | 1,701,255,073.49 | 443,433,667 |
| 负债合计 | 5,783,381,581.83 | 7,146,776,162.93 | 8,070,492,359.49 | 8,295,022,482.91 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 64,466,430,205.71 | 63,626,264,350.1 | 61,272,068,641.41 | 59,504,250,787.19 |
| 股东权益合计 | 64,989,740,417.06 | 64,147,086,277.95 | 61,796,823,414.25 | 60,032,518,002.87 |
| 负债和股东权益合计 | 70,773,121,998.89 | 71,293,862,440.88 | 69,867,315,773.74 | 68,327,540,485.78 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 14,357,158,249.68 | 6,924,351,344.85 | 34,834,159,889.58 | 26,972,822,783.38 |
| 经营活动现金流出小计 | 12,370,154,377.34 | 6,137,905,444.14 | 23,598,781,758.95 | 17,862,392,493.11 |
| 经营活动产生的现金流量净额 | 1,987,003,872.34 | 786,445,900.71 | 11,235,378,130.63 | 9,110,430,290.27 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 68,206,934.09 | 11,372,939.06 | 221,403,914.71 | 188,195,561.47 |
| 投资活动现金流出小计 | 1,892,805,322.86 | 735,118,964.87 | 2,961,906,284.58 | 1,714,462,484.69 |
| 投资活动产生的现金流量净额 | -1,824,598,388.77 | -723,746,025.81 | -2,740,502,369.87 | -1,526,266,923.22 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,491,095,462.51 | 299,534,222.25 | 12,265,679,059.4 | 10,780,273,195.06 |
| 筹资活动现金流出小计 | 3,080,882,038.32 | 485,251,178.59 | 4,483,971,687.7 | 2,689,252,803.88 |
| 筹资活动产生的现金流量净额 | -1,589,786,575.81 | -185,716,956.34 | 7,781,707,371.7 | 8,091,020,391.18 |
| 汇率变动对现金及现金等价物的影响 | -696,646,671.36 | -349,701,516.56 | -360,132,552.71 | -146,577,748.58 |
| 现金及现金等价物净增加额 | -2,124,027,763.6 | -472,718,598 | 15,916,450,579.75 | 15,528,606,009.65 |
| 期末现金及现金等价物余额 | 38,031,524,933.81 | 39,682,834,099.41 | 40,155,552,697.41 | 39,767,708,127.31 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -2,124,027,763.6 | - | 15,916,450,579.75 | - |
最新报告期：2026-09-17| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 浙商证券 | 郭双喜 | 1.42 | 1.61 | 1.90 | 2026-09-17 |
| 中信建投 | 沈毅,袁清慧,贺菊颖 | 1.39 | 1.47 | 1.74 | 2026-09-03 |
| 东方证券 | 伍云飞 | 1.35 | 1.46 | 1.86 | 2026-08-31 |
| 首创证券 | 王斌 | 1.36 | 1.54 | 1.83 | 2026-08-25 |
| 中邮证券 | 陈灿,盛丽华 | 1.28 | 1.47 | 1.73 | 2026-08-24 |